1. Search Result
Search Result
Results for "

MPP+

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Natural
Products

2

Recombinant Proteins

2

Isotope-Labeled Compounds

14

Antibodies

10

Oligonucleotides

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-15608
    MPTP hydrochloride
    Maximum Cited Publications
    86 Publications Verification

    Dopamine Receptor Apoptosis Neurological Disease Inflammation/Immunology
    MPTP hydrochloride is a brain penetrant dopaminergic neurotoxin. MPTP hydrochloride can be used to induce Parkinson’s Disease model. MPTP hydrochloride, a precusor of MPP +, induces apoptosis . MPTP hydrochloride has been verified by MCE with professional biological experiments.
    MPTP hydrochloride
  • HY-W008719
    MPP+ iodide
    30+ Cited Publications

    Mitochondrial Metabolism Neurological Disease
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
    MPP+ iodide
  • HY-103454
    MPP dihydrochloride
    15+ Cited Publications

    Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP dihydrochloride
  • HY-W114750
    MPTP
    Maximum Cited Publications
    86 Publications Verification

    Dopamine Receptor Apoptosis Neurological Disease Inflammation/Immunology
    MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a brain penetrant dopamine neurotoxin. MPTP can be used to induce Parkinson’s Disease model. MPTP, a precusor of MPP +, induces apoptosis .
    MPTP
  • HY-103454B
    MPP hydrochloride
    15+ Cited Publications

    Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP hydrochloride
  • HY-B0596
    Taltirelin
    1 Publications Verification

    TA-0910

    Thyroid Hormone Receptor Apoptosis Neurological Disease Endocrinology
    Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
    Taltirelin
  • HY-129096
    IDT307
    2 Publications Verification

    Fluorescent Dye Others
    IDT307, an analog of the organic cation MPP+, is a specific fluorescent substrate for DAT (fluorescent substrate APP+) .
    IDT307
  • HY-134205A
    CBR-470-1
    3 Publications Verification

    Keap1-Nrf2 Neurological Disease Metabolic Disease
    CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP +-induced cytotoxicity through activation of the Keap1-Nrf2 cascade .
    CBR-470-1
  • HY-B0764B

    Dibutyryl cAMP; DBcAMP

    PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine
  • HY-W115752

    Diamine sulfate (99%)

    PEPCK Aldehyde Dehydrogenase (ALDH) Neurological Disease Metabolic Disease Cancer
    Hydrazine sulfate is an orally active PEPCK inhibitor. Hydrazine sulfate inhibits PEPCK and low-Km ALDH. Hydrazine sulfate impairs gluconeogenesis and enhances the protective effect of energy substrates against MPP + toxicity. Hydrazine sulfate exacerbates liver damage in rats when combined with Ethanol. Hydrazine sulfate can be used in the research of shock, non-small cell lung cancer, colorectal cancer and Parkinson's disease .
    Hydrazine sulfate (99%)
  • HY-160959

    nAChR Neurological Disease
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
    AN317
  • HY-B0596A
    Taltirelin acetate
    1 Publications Verification

    TA-0910 acetate

    Thyroid Hormone Receptor Apoptosis Neurological Disease Endocrinology
    Taltirelin acetate (TA-0910) is an acetate form of Taltirelin (TA-0910). Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
    Taltirelin acetate
  • HY-W008719S

    Mitochondrial Metabolism Neurological Disease
    MPP+-d3 (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
    MPP+-d3iodide
  • HY-155126

    Reactive Oxygen Species (ROS) Neurological Disease
    LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP +-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .
    LZWL02003
  • HY-136903

    Calcium Channel Proteasome Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Inflammation/Immunology
    SNJ-1945 is an orally active Calpain inhibitor that can cross the blood-brain barrier. SNJ-1945 protects rat hearts against cardiac arrest-reperfusion injury by inhibiting the hydrolysis of α-fodrin. SNJ-1945 inhibits VEGF-induced angiogenesis in retinal endothelial cells. SNJ-1945 also protects SH-SY5Y cells from damage induced by MPP+ (HY-W008719) and Rotenone (HY-B1756). SNJ-1945 exhibits anti-inflammatory and neuroprotective activities in a mouse model of multiple sclerosis. SNJ-1945 can be used for the research of cardiovascular, nervous system and inflammatory diseases .
    SNJ-1945
  • HY-127133

    MPP

    Estrogen Receptor/ERR Endocrinology
    Methylpiperidino pyrazole (MPP) is a potent and selective ER (estrogen receptor) modulator. Methylpiperidino pyrazole induces significant apoptosis in the endometrial cancer and oLE cell lines. Methylpiperidino pyrazole reverses the the positive effects of beta-estradiol. Methylpiperidino pyrazole has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    Methylpiperidino pyrazole
  • HY-125693

    Fungal Infection Neurological Disease
    L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans .
    L685818
  • HY-138967

    Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    BRF110 is the selective, orally active rexinoid for Nurr1-RXRα, that selectively activates the Nurr1-RXRα heterodimer with an EC50 of 0.9 μM in SH-SY5Y. BRF110 upregulates the expression of BDNF, exhibits neuroprotective activity against MPP+ induced toxicity. BRF110 can cross blood-brain barrier .
    BRF110
  • HY-RS25845

    Small Interfering RNA (siRNA) Others

    Mpp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mpp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mpp2 Rat Pre-designed siRNA Set A
    Mpp2 Rat Pre-designed siRNA Set A
  • HY-RS08624

    Small Interfering RNA (siRNA) Others

    MPP3 Human Pre-designed siRNA Set A contains three designed siRNAs for MPP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPP3 Human Pre-designed siRNA Set A
    MPP3 Human Pre-designed siRNA Set A
  • HY-RS08625

    Small Interfering RNA (siRNA) Others

    MPP4 Human Pre-designed siRNA Set A contains three designed siRNAs for MPP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPP4 Human Pre-designed siRNA Set A
    MPP4 Human Pre-designed siRNA Set A
  • HY-RS08622

    Small Interfering RNA (siRNA) Others

    MPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for MPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPP1 Human Pre-designed siRNA Set A
    MPP1 Human Pre-designed siRNA Set A
  • HY-RS08626

    Small Interfering RNA (siRNA) Others

    MPP7 Human Pre-designed siRNA Set A contains three designed siRNAs for MPP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPP7 Human Pre-designed siRNA Set A
    MPP7 Human Pre-designed siRNA Set A
  • HY-RS19354

    Small Interfering RNA (siRNA) Others

    Mpp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mpp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mpp2 Mouse Pre-designed siRNA Set A
    Mpp2 Mouse Pre-designed siRNA Set A
  • HY-RS08623

    Small Interfering RNA (siRNA) Others

    MPP2 Human Pre-designed siRNA Set A contains three designed siRNAs for MPP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPP2 Human Pre-designed siRNA Set A
    MPP2 Human Pre-designed siRNA Set A
  • HY-RS22082

    Small Interfering RNA (siRNA) Others

    Mpz Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mpz gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mpz Mouse Pre-designed siRNA Set A
    Mpz Mouse Pre-designed siRNA Set A
  • HY-150918S

    Isotope-Labeled Compounds Others
    3-(3-Methyl-1H-Prazol-5-yl)Propanoic Acid (MPP) Methyl,pyrazol yl- 13C5 is the 13C labeled 3-(3-Methyl-1H-Prazol-5-yl)Propanoic Acid (MPP) Methyl,pyrazol yl .
    5-Methyl-1H-pyrazole-3-propanoic acid-13C5
  • HY-N12657

    Others Neurological Disease
    Retinestatin, a new polyol polyketide, can protect SH-SY5Y dopaminergic cells from MPP + (HY-W008719)-induced cytotoxicity. Retinestatin shows neuroprotective effects in an in vitro model of Parkinson’s disease .
    Retinestatin
  • HY-RS08633

    Small Interfering RNA (siRNA) Others

    MPZ Human Pre-designed siRNA Set A contains three designed siRNAs for MPZ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MPZ Human Pre-designed siRNA Set A
    MPZ Human Pre-designed siRNA Set A
  • HY-163189

    Bcr-Abl Neurological Disease
    c-ABL-IN-6 (compound A6) is a c-ABL inhibitor with IC50 value of 16.6 nM. c-ABL-IN-6 displays higher neuroprotective effects against SH-SY5Y cell death induced by MPP + (HY-W008719). c-ABL-IN-6 can be used for the research of neurodegenerative disorder .
    c-ABL-IN-6
  • HY-116202

    Keap1-Nrf2 Reactive Oxygen Species (ROS) Neurological Disease
    PACA is an enhancer of nerve growth factor-induced neurite outgrowth, enhancing nerve growth factor (NGF)-induced neurite outgrowth and attenuating 6-hydroxydopamine (6-OHDA)-induced toxicity by activating the Nrf2/HO-1 pathway. PACA has neuroprotective and neurogenic activities. PACA can be used to improve dopaminergic neuron loss and motor dysfunction in MPTP mouse models of Parkinson's disease and MPP +-induced neurons .
    PACA
  • HY-103454BR

    Reference Standards Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP hydrochloride (Standard) is the analytical standard of MPP hydrochloride (HY-103454B). This product is intended for research and analytical applications. MPP hydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP hydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP hydrochloride reverses the the positive effects of beta-estradiol. MPP hydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP hydrochloride (Standard)
  • HY-103454R

    Reference Standards Estrogen Receptor/ERR Apoptosis Endocrinology Cancer
    MPP dihydrochloride (Standard) is the analytical standard of MPP dihydrochloride (HY-103454). This product is intended for research and analytical applications. MPP dihydrochloride is a potent and selective ER (estrogen receptor) modulator. MPP dihydrochloride induces significant apoptosis in the endometrial cancer and oLE cell lines. MPP dihydrochloride reverses the positive effects of beta-estradiol. MPP dihydrochloride has mixed agonist/antagonist action on murine uterine ERalpha in vivo .
    MPP dihydrochloride (Standard)
  • HY-103216A

    Adrenergic Receptor Neurological Disease
    RWJ-52353 hydrochloride is an orally potent, highly selective α2D adrenergic receptor agonist (Ki: 1.5 nM) with potential analgesic effects. RWJ-52353 hydrochloride demonstrated analgesic activity in abdominal tests in rats and mice, and improved agitation in mice in the hot plate test and tail flick test. RWJ-52353 hydrochloride also regulates the organic cation transporter (OCT) subtype, inhibiting rOCT1 and rOCT2 with IC50s of 100 μM and 20 μM respectively; it also activates rOCT3, affecting [3H]-1- in cells. Methyl-4-phenylpyridinium ([3H]MPP) transport .
    RWJ52353 hydrochloride
  • HY-N18155

    (1(10)E,2α,4β,8α)-form,2-Meether

    Others Neurological Disease
    2-Hydroxy-6-oxo-1(10),7(11)-germacradien-12,8-olide ((1(10)E,2α,4β,8α)-form,2-Meether) is a furanosesquiterpenoid neuroprotective agent that exhibits neuroprotective effect against MPP +-induced neuronal cell death. 2-Hydroxy-6-oxo-1(10),7(11)-germacradien-12,8-olide can be used for the research of parkinson's disease .
    2-Hydroxy-6-oxo-1(10),7(11)-germacradien-12,8-olide
  • HY-W152736

    DYRK Neurological Disease
    2-Methyl-5-acetylphenol is a hydroxylated methylacetophenone that exists in the aerial parts of Cannabis sativa subsp. sativa. 2-Methyl-5-acetylphenol exhibits strong binding affinity to HIPK2. 2-Methyl-5-acetylphenol cannot reverse MPP + (1-methyl-4-phenyl-pyridinium ion)-induced neuronal cytotoxicity. 2-Methyl-5-acetylphenol can be used for Parkinson's disease research .
    2-Methyl-5-acetylphenol
  • HY-RS28602

    Small Interfering RNA (siRNA) Others
    Mpz Rat Pre-designed siRNA Set A contains three designed siRNAs for Mpz gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mpz Rat Pre-designed siRNA Set A
    Mpz Rat Pre-designed siRNA Set A
  • HY-172763

    Drug Derivative Serotonin Transporter Dopamine Transporter 5-HT Receptor Neurological Disease
    EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC50 = 117 nM) and MPP + releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM) .
    EDMA hydrochloride
  • HY-119612

    XCT

    Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC50 value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP +. XCT0135908 can be used for the research of Parkinson’s disease .
    XCT0135908

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

 

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

 

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: